A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
about
Expression in Yeast Links Field Polymorphisms in PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor ClassesDrug delivery of the future: Chasing the invisible gorillaInternational Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsMedicinal chemistry and the pharmacy curriculumChemoenzymatic synthesis of diverse thiohydroximates from glucosinolate-utilizing enzymes from Helix pomatia and Caldicellulosiruptor saccharolyticus.Opportunities to minimise risk in drug discovery and development.Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL MiceStrategies for discovering and derisking covalent, irreversible enzyme inhibitors.Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.The impact of proton pump inhibitors on the human gastrointestinal microbiomeHuman pharmacogenomic variations and their implications for antifungal efficacy.The value of branded proton pump inhibitors: formulary considerations.Designing Irreversible Inhibitors--Worth the Effort?Proton pump inhibitors affect the gut microbiome.Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancerA methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer.Acid suppression therapy: where do we go from here?Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosaChemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Combining Chemometric Models with Adsorption Isotherm Measurements to Study Omeprazole in RP-LC.Emerging drugs for gastroesophageal reflux disease.Vagotomy and Gastric TumorigenesisAntitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.Esomeprazole: potent acid suppression in the treatment of acid-related disorders.Systematic review: hypomagnesaemia induced by proton pump inhibition.Identification of a novel benzimidazole that inhibits bacterial biofilm formation in a broad-spectrum mannerLysine-Targeting Covalent Inhibitors.Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.Current Knowledge and Perspectives on Histamine H1 and H2 Receptor Pharmacology: Functional Selectivity, Receptor Crosstalk, and Repositioning of Classic Histaminergic Ligands.Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis.Plasma membrane-associated glycohydrolases activation by extracellular acidification due to proton exchangers.Micromotor-enabled active drug delivery for in vivo treatment of stomach infection.Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Deracemization of a Racemic Allylic Sulfoxide Using Viedma Ripening.The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors.Omeprazole decreases magnesium transport across Caco-2 monolayers.
P2860
Q22061833-3BA1D9F3-60AA-4BB6-862F-5F433BBA983EQ24289432-30061C20-EB76-4CD7-A666-94A52EEC4EA5Q26827568-B6B6D7C6-341A-4656-94F3-A66AF3825C2BQ27023753-5E17E323-F81A-4128-9525-4174E8801933Q30318487-CB1A98B1-E0EA-4A2D-85BF-CE2D5CDAE252Q30428283-B5E937C9-46AF-4836-88D3-49914082F90AQ31116734-8BB1D62F-4436-4F52-8CB1-35D08A040423Q34023143-F43F902C-FF2F-4784-B3B0-EB7933E949F4Q34160457-D9157883-F0EE-428E-93A5-FCE0258AEC0BQ34573748-9F79AC61-7CF3-4822-B1D7-D0462455DEECQ34625008-FFFAE2D1-97A9-41BE-B699-5848D1639809Q35070838-4DA8ECED-EBE9-4DCF-95BF-20F6D0E112A8Q35209935-7F108F95-9302-40C5-9F58-8EFB2703F233Q35848315-E80BBC41-4DF6-4B8A-8751-F2AC84FDC831Q35866595-89D7B34C-17A1-4A8A-9A60-638EEA021E7CQ35987082-71204687-1D6C-4908-862C-F373A472C240Q36386030-90DB6D30-6E61-4BE1-B2CA-B82BF610A40CQ36478082-9F966A8A-DA8F-4F37-8E92-6D097C65B32AQ36572905-94AE8255-DAAB-4310-8386-2811BF6FCCD5Q36662875-D288710E-039F-4FAD-A3CB-0CB5BCEAD3E9Q37290097-9FFEEB6E-8912-4DC7-8357-E1A4BE84BB58Q37570546-DB4922DC-9A7D-4F8D-8E07-02FC79237802Q37677019-FA89D22C-5E0B-4AB3-BAE1-A1E8FCE2F721Q37706150-0399EC04-6E08-4DC1-B631-75330E29FF9FQ37755220-32369E69-124F-4FB4-9788-0C4575F2DB51Q38023882-7AEC82D6-DFD1-4196-B23F-787AD9102A14Q38282786-6DFA40C9-F1AE-412E-94FB-D66A0ACAE450Q38635726-9CF9ADAC-AE9D-44A1-B54C-84483D65E454Q38773386-A5A37622-ADD6-472C-9D9F-F8B861A0A0F9Q38865456-3267BC80-964E-4243-8129-581E980091B5Q38907268-245BF234-99D9-487B-824B-8C4F199B9CD7Q38953768-42935E5C-AF41-4561-819A-81CA0AA088DFQ39215455-D99FB9A0-9FFF-497C-BAC3-50E63FAAFD38Q39251528-8569D3DC-50FF-4C47-B87F-3B13A65F4163Q39391765-E0A28BF5-2D20-46EA-B528-962E554163B9Q40090937-2C2E9B86-A9A1-416D-B102-CC60B9C18522Q40316973-EA7C36CA-B01D-4FDA-8B6C-70BAEBAEC36DQ41246716-F9421A13-05E9-4DAD-A4E2-A33CECF2C47CQ41779445-AF0C7D3D-C0C7-427F-8121-D5F317D5C465Q41982621-4FEC90A4-38F8-4A4D-88EF-6B1EDA241CA4
P2860
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@ast
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@en
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@nl
type
label
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@ast
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@en
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@nl
prefLabel
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@ast
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@en
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@nl
P2093
P356
P1476
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
@en
P2093
Enar Carlsson
Per Lindberg
P2888
P304
P356
10.1038/NRD1010
P577
2003-02-01T00:00:00Z
P5875
P6179
1037219697